Experimental models of endocrine responsive breast cancer: strengths, limitations, and use
作者机构：The Hormel Institute and Department of BiochemistryMolecular Biology and BiophysicsUniversity of MinnesotaAustinMN 55912USA Department of OncologyGeorgetown University Medical CenterWashingtonDC 20057USA The Jackson Laboratory600 Main StreetBar HarborME 04609USA
出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)
年 卷 期：2021年第4卷第4期
页 面：762-783页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：supported by grants from the from the Department of Defense Breast Cancer Research Program(CA171885) from the National Cancer Institute(U01CA184902)to Dr.Clarke
主 题：Breast cancer experimental models PDX xenografts study design
摘 要：Breast cancers characterized by expression of estrogen receptor-alpha(ER;ESR1)represent approximately 70%of all new cases and comprise the largest molecular subtype of this *** this high prevalence,the number of adequate experimental models of ER+breast cancer is relatively ***,these models have proved very useful in advancing understanding of how cells respond to and resist endocrine therapies,and how the ER acts as a transcription factor to regulate cell fate *** discuss the primary experimental models of ER+breast cancer including 2D and 3D cultures of established cell lines,cell line-and patient-derived xenografts,and chemically induced rodent models,with a consideration of their respective general strengths and *** can and cannot be learned easily from these models is also discussed,and some observations on how these models may be used more effectively are ***,despite their limitations,the panel of models currently available has enabled major advances in the field,and these models remain central to the ability to study mechanisms of therapy action and resistance and for hypothesis testing that would otherwise be intractable or unethical in human subjects.
维普期刊数据库